Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer
- 14 April 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (8), 2466-2473
- https://doi.org/10.1158/1078-0432.ccr-09-3015
Abstract
Purpose: We have shown the feasibility of administering inhaled doxorubicin to patients with cancer. This study evaluated inhaled doxorubicin combined with cisplatin and docetaxel in patients with non–small cell lung cancer. The principal objective was to determine safety and, secondarily, efficacy. Experimental Design: Patients who had chemo-naïve advanced non–small cell lung cancer were enrolled in the study. Adequate organ and pulmonary function was required: diffusing capacity for carbon monoxide/forced expiratory volume in 1 second/forced vital capacity ≥50%, resting/exercise O2 saturation ≥90%/85%. In phase I, doxorubicin was escalated: dose level 1 (6 mg/m2) and level 2 (7.5 mg/m2). Escalation was permitted if ≤2 of 6 patients experienced pulmonary dose-limiting toxicity (grade 2 Radiation Therapy Oncology Group lung morbidity; resting O2 saturation of 2. Treatments and pulmonary function tests were repeated every 21 days, with up to eight cycles for responding patients. Results: Twenty-eight patients were treated at level 1 and eight patients at level 2. Doxorubicin was escalated to 7.5 mg/m2, however, after two patients developed pulmonary dose-limiting toxicity; the remainder were treated at 6.0 mg/m2. Twenty-four evaluable patients received at least two courses or had progressive disease following the first course at the phase II dose. Toxicity was associated with i.v. chemotherapy although one patient had delayed pulmonary toxicity responding to corticosteroids and oxygen. Seven (29%) evaluable patients responded (six partial responses and one complete response) and 13 (54%) patients had stable disease for up to eight cycles. Conclusion: Although this combination was safe, the primary objective was not met and will not be pursued further. Clin Cancer Res; 16(8); 2466–73. ©2010 AACR.Keywords
This publication has 31 references indexed in Scilit:
- An Update on the Use of Intraperitoneal Chemotherapy in the Management of Ovarian CancerThe Cancer Journal, 2009
- The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III StudiesThe Oncologist, 2009
- A Dose-Escalation Study of Aerosolized Sargramostim in the Treatment of Metastatic MelanomaAmerican Journal of Clinical Oncology, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the LungClinical Cancer Research, 2007
- Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the LungsClinical Cancer Research, 2007
- Clinical Evaluation of the Delivery and Safety of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Pulmonary MalignanciesClinical Cancer Research, 2004
- Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study GroupJournal of Clinical Oncology, 2003
- Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon ? in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatmentZeitschrift für Krebsforschung und Klinische Onkologie, 1994
- N-Methylcarbamate derivatives of ellipticine and olivacine with cytotoxic activity against four human lung cancer cell linesJournal of Medicinal Chemistry, 1992